StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
VIVS

VivoSim Labs, Inc.

VIVS Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$0.33
-0.06 -14.21%

Key statistics

from XBRL data in SEC filings
Market cap
$1.17M
Revenue (TTM)
$131K
Net income (TTM)
-$13.8M
EPS (TTM)
$-5.35
P/E ratio
Dividend yield
Free cash flow
Cash
$5.02M
Total assets
$7.39M
Gross margin
52-week range
$0.31 – $5.30

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Item 5.08; Other events Jul 30, 2026 8-K Delisting notice or listing-rule failure; Other events Jul 24, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Jul 17, 2026 10-K Fiscal year ended 2026-03-31 Jul 14, 2026 8-K Entered a material agreement; Other events Apr 3, 2026 10-Q Quarter ended 2025-12-31 Feb 11, 2026 8-K Shareholder vote results Dec 18, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Director or officer change; Regulation FD disclosure Aug 14, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 10-K/A Fiscal year ended 2025-03-31 Jul 29, 2025 10-K Fiscal year ended 2025-03-31 Jun 5, 2025 8-K Other events May 6, 2025 8-K Amended charter or bylaws; Regulation FD disclosure; Other events Apr 24, 2025 8-K Regulation FD disclosure Apr 23, 2025 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Apr 2, 2025 8-K Regulation FD disclosure Mar 27, 2025 8-K Completed an acquisition or disposition; Director or officer change; Other events Mar 26, 2025 8-K Modified rights of security holders; Amended charter or bylaws Mar 21, 2025 8-K Regulation FD disclosure Mar 19, 2025 8-K Other events Mar 6, 2025 8-K Entered a material agreement; Delisting notice or listing-rule failure; Other events Feb 25, 2025 10-Q Quarter ended 2024-12-31 Feb 19, 2025 8-K Delisting notice or listing-rule failure Jan 17, 2025 8-K Director or officer change Dec 31, 2024 8-K Director or officer change; Shareholder vote results Nov 22, 2024 10-Q Quarter ended 2024-09-30 Nov 8, 2024 8-K Director or officer change Aug 9, 2024 10-Q Quarter ended 2024-06-30 Aug 5, 2024 10-K/A Fiscal year ended 2024-03-31 Jul 26, 2024 8-K Delisting notice or listing-rule failure Jul 24, 2024 10-K Fiscal year ended 2024-03-31 May 31, 2024 8-K Entered a material agreement; Other events May 13, 2024 8-K Regulation FD disclosure May 1, 2024 8-K Other events Apr 23, 2024 10-Q Quarter ended 2023-12-31 Feb 8, 2024 8-K Regulation FD disclosure Feb 7, 2024 8-K Unregistered sale of equity; Other events Dec 28, 2023 10-Q Quarter ended 2023-09-30 Nov 9, 2023 8-K Director or officer change; Shareholder vote results Nov 3, 2023